177 related articles for article (PubMed ID: 24766821)
21. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
23. Taking cancer-drug toxicity to heart.
Rose S
Cancer Discov; 2013 Feb; 3(2):132. PubMed ID: 23400461
[No Abstract] [Full Text] [Related]
24. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Turan N; Benekli M; Ozturk SC; Inal S; Memis L; Guz G; Cetin B; Buyukberber S
Ann Pharmacother; 2012 Oct; 46(10):e27. PubMed ID: 23032654
[TBL] [Abstract][Full Text] [Related]
25. [Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Joly F
Bull Cancer; 2011 Oct; 98(9):1071-81. PubMed ID: 21914577
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
27. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Deslandres M; Sibaud V; Chevreau C; Delord JP
Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
[TBL] [Abstract][Full Text] [Related]
28. A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
P J G; A M; L M; H J H; M K; S B; N M
Urol Oncol; 2014 Apr; 32(3):362-70. PubMed ID: 24321255
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
30. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
Phillip V; Zahel T; Bärtl K; Rasch S; Ebert O; Schmid RM; Rummeny E; Algül H
Pancreatology; 2016; 16(4):621-4. PubMed ID: 26968257
[TBL] [Abstract][Full Text] [Related]
31. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Grandinetti CA; Goldspiel BR
Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
[TBL] [Abstract][Full Text] [Related]
32. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Porta C; Paglino C; Imarisio I; Bonomi L
Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524
[TBL] [Abstract][Full Text] [Related]
33. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
34. How to manage hypersensitivity reactions to biological agents?
Barbaud A; Granel F; Waton J; Poreaux C
Eur J Dermatol; 2011; 21(5):667-74. PubMed ID: 21742594
[TBL] [Abstract][Full Text] [Related]
35. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
36. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
37. [New drugs; sunitinib and sorafenib].
Bellersen L
Ned Tijdschr Geneeskd; 2008 Feb; 152(8):469-70; author reply 470. PubMed ID: 18363211
[No Abstract] [Full Text] [Related]
38. Progress in the management of advanced renal cell carcinoma (RCC).
Tong TQ; Rohde D; Peter S
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
[TBL] [Abstract][Full Text] [Related]
39. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
[No Abstract] [Full Text] [Related]
40. Perforating folliculitis-like reaction related to sorafenib.
Eberst E; Rigau V; Pageaux GP; Guillot B; Kluger N
Cutis; 2014 Jan; 93(1):E8-10. PubMed ID: 24505595
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
